Investment
Features
FeesSafety
Academy
More
Pluang+

Pfizer's cancer drugs boost Q4 sales; Talzenna up 81.5%, driving strong start to 2026.

Company Fundamentals
27 Mar 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Pfizer began 2026 strongly with robust Q4 sales of its key anti-cancer drugs, including an 81.5% year-on-year rise in Talzenna sales to $49 million. The company also announced that Talzenna combined with Xtandi met the primary endpoint in a prostate cancer trial, highlighting its growth potential. Following its Q4 report, Pfizer's stock rose 7%, outperforming the broader market. These results reinforce Pfizer's position as a strong buy for investors focused on pharmaceutical growth.

More News (PFE)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App